HSP90AA1 and head and neck squamous cell carcinoma: Yin et al. reported that both BIIB021, an HSP90 inhibitor based on the purine scaffold, and 17-AAG showed anticancer effects on head and neck squamous cell carcinoma (HNSCC) xenografts as a single agent.